IDENTIFYING NOVEL THERAPEUTIC TARGETS AND COMBINATION STRATEGIES FOR PATIENTS WITH BPDCN

$973,500FY2020Defense Health AgencyDOD

Dana-Farber Cancer Institute, Inc.

Investigators